ABSTRACT
INTRODUCTION
Congestive heart failure (CHF) affects 5 million people in the US with high morbidity and mortality 1 . The poor pump function of the failing heart induces chronic activation of neuroendocrine systems that supports cardiac performance but can also activate death signaling to cause CHF progression.
Persistent activation of the sympathoadrenergic system (SAS) in CHF can cause adverse cardiac remodeling, cardiac myocyte death and fibrosis replacement 2 . Reducing myocyte death has been proposed as one of the mechanisms responsible for the beneficial effects of -blockers in heart failure patients 3 . The mechanisms of -adrenergic mediated myocyte death are still not clearly defined and are the focus of this study. Some studies suggest that PKA is the mediator of -adrenergic induced myocyte apoptosis by altering Ca 2+ regulation 4, 5 , while others have suggested that Ca 2+ /camodulin-dependent kinase II (CaMKII) can mediate -adrenergic induced myocyte death through a PKA-independent process [6] [7] [8] [9] [10] . A cAMP sensor, exchange protein directly activated by cAMP (EPAC), is expressed in the heart and has been suggested to activate CaMKII independent of PKA [6] [7] [8] .
The hypothesis of this study is that -adrenergic mediated myocyte death requires PKA activation and subsequently enhanced Ca 2+ signaling, but is independent of EPAC. To test this idea, we designed a PKA-specific inhibition gene (a fusion gene containing the nucleotide sequence coding the amino acids 1-25 of PKI and GFP (PKI-GFP)). PKI-GFP was expressed in the mouse heart or in cultured adult feline ventricular myocytes (AFVMs). Our major findings are that: (1) -agonists activated both PKA and EPAC, and PKI-GFP inhibited only PKA activation; (2) -adrenergic agonists induced myocyte death is blocked by PKI; (3) PKA inhibition prevented myocyte death induced by -adrenergic agonists by abolishing -adrenergic effects on myocyte Ca 2+ handling; (4) -AR induced CaMKII activation was dependent on PKA activation; (5) EPAC did not promote myocyte apoptosis but instead protected myocytes from apoptosis by activating the pro-survival signal ERK; (6) PKA inhibition was superior to a -blocker, metoprolol, to improve cardiac function after myocardial infarction (MI); (7) Metoprolol eliminated the beneficial effects of PKI after MI. Our results suggest that selective inhibition of PKA would be an effective therapy in heart failure patients.
METHODS
A DNA oligo corresponding to the coding sequence for amino acids 1-25 of mouse protein kinase inhibitor  (PKI) (mouse Entrez gene ID 18767) was synthesized and subcloned into a plasmid to make a PKI-GFP fusion gene. Amino acids 1-25 of PKI have the PKA inhibitory domain 11 but not the nuclear export signal 12 . Then an adenovirus containing the fusion gene and a transgenic mouse line overexpressing this fusion gene were established 13 . Doxycycline-containing (625ppm) chow was offered to breeding animals and preweaned pups. Transgenic and littermate control animals were used at the age of 4 months. To test -adrenergic overstimulation on cardiac myocyte death, acute isoproterenol (ISO, 60mg/kg) or chronic ISO (60mg/kg/day, 3 weeks) were applied 14 . Echocardiography (ECHO), cardiac morphology, gravimetric measurements, tissue histology and TUNEL staining were done at the end of 3 weeks 14 . To explore PKA-dependent and -independent mechanisms of myocyte apoptosis induced by -AR signaling, adult feline ventricular myocytes (AFVMs) were isolated, cultured and infected with AdGFP (control) or AdPKI-GFP 15 . The inhibition of PKA by PKI-GFP was determined with a nonradioactive PKA activity kit (Assay Design, Ann Arbor, MI) and cAMP production upon ISO stimulation was determined with [ 3 H]-adenine and radioactivity incorporation into newly synthesized cAMP. Myocyte death was determined by trypan blue staining, rod/ball ratio counting, TUNEL and FLICA staining. Myocyte contractions and intracellular Ca 2+ transients, Ca 2+ currents and SR Ca 2+ content were measured as previously described 16 . To determine the activity of PKA and CaMKII, phospholamban phosphorylation at Ser16 and Thr17, and CaMKII phosphorylation at Thr286 were determined with Western blot. Western blot was also used to determine activated Rap1 that bound to GTP (Rap1GTP), ERK and pERK. To determine the effect of -blockade on the protection of PKI in postmyocardial infarction (MI) mice, littermate control and PKI DTG mice were injected with saline or metoprolol (20mg/kg BW/day) daily 17 for 4 weeks. Cardiac function was followed weekly with ECHO.
An expanded "Materials and Methods" can be found in the Supplemental Data.
RESULTS

PKI-GFP is evenly expressed in the mouse heart to suppress PKA activity.
The PKI-GFP double transgenic (DTG) mouse began to express PKI-GFP at 2 months and had stable expression by 4 months of age ( Figure 1A ). PKI-GFP was expressed in DTG mice but not in PKI-GFP single transgenic (STG), tTA only and wild -type (WT) mice ( Figure 1B ). Homogenous GFP fluorescence was seen in DTG hearts but no GFP fluorescence was observed in PKI-GFP STG hearts ( Figure 1C ). In isolated ventricular myocytes, the GFP fluorescence was evenly distributed in the whole cell ( Figure 1D ). There was little PKA activity at baseline in both control and DTG hearts. However, when PKA activity in crude cardiac tissue extract was measured in the presence of 1M cAMP, PKA activity was almost completely inhibitedin PKI transgenic samples ( Figure 1E ).
PKI-GFP prevents cardiac dysfunction and myocyte death induced by isoproterenol.
We first examined if -adrenergic induced myocyte death was PKA dependent (in vivo) by measuring the effect of ISO on myocyte apoptosis in the PKI DTG mice. Chronic ISO infusion into PKI transgenic and control mice for 3 weeks induced cardiac hypertrophy and depressed cardiac function in control animals but not in PKI transgenic mice (Figure 2A and B) . Chronic ISO infusion caused significant fibrosis in control cardiac tissue but not in PKI DTG tissue ( Figure 2C and D). There were significant increases in TUNEL + cardiac myocyte nuclei in control cardiac tissues but not in PKI DTG tissue ( Figure 2E) . A single injection of ISO into PKI DTG and control mice induced a higher percentage of TUNEL + cardiac myocytes in control myocardium than in PKI DTG myocardium ( Figure 2F ).
PKI-GFP overexpression in cultured adult feline ventricular myocytes (AFVMs) prevents PKA activation but does not affect ISO-induced cAMP production.
different between the groups. 1M cAMP increased the PKA activity in the crude extract from AdGFP infected cells but not in the crude extract from AdPKI infected cells ( Figure 3C ). When these two groups of myocytes were exposed to 10M ISO for 10 minutes in the presence of a PDE inhibitor, IBMX, the total amount of cAMP produced was not different between groups ( Figure 3D ), showing no change of -adrenergic signaling upstream of PKA.
PKI prevents myocyte apoptosis induced by -adrenergic agonists in AFVMs.
Excessive -AR stimulation can lead to myocyte death via apoptosis 18 . AdPKI-GFP infected AFVMs (PKI-AFVMs) were exposed to -AR agonists to induce myocyte death. PKI-AFVMs were completely protected from cell death induced by ISO (a nonselective 1-AR and 2-AR agonist, 10M) ( Figure 4A &B) . The survival of VMs exposed to 10M ISO for 72 hours was increased when AdPKI-GFP MOI was increased from 10 to 100 ( Figure 4C ). This protection effect was associated with reduced myocyte apoptosis measured by TUNEL and FLICA (an index of caspase activity) ( Figure 4D ). These results do not agree with a previous study showing that exogenous PKA inhibitors could not rescue rodent myocyte death induced by -AR activation 19 . This could be due to the fact that our studies were performed with AFVMs which possess physiological properties similar to human ventricular myocytes and do not accumulate Ca 2+ under unpaced culture condition 20 . Rodent myocytes accumulate Ca 2+ , have SR Ca 2+ overload in culture and have a high rate of apoptosis without -adrenergic agonists 20 . Any residual unblocked PKA effect would enhance SR Ca 2+ overload in rodents while these effects are absent in AFVMs.
-adrenergic toxicity is mediated by 1-adrenergic receptor and linked to cAMP/PKA activation. Dobutamine (a 1-AR agonist), ISO+ICI 118551 (a 2-AR antagonist, 2M), ISO+CGP 20712A (a 1-AR antagonist, 6M), fenoterol (a 2-AR agonist, 10M), and forskolin (an AC activator) were used to determine the effect of-AR vs. 2-AR activation on myocyte death ( Figure 4F) . Dobutamine, ISO+ICI, and forskolin induced myocyte death that was rescued by PKI-GFP. These results suggest that 1-AR activation and subsequent adenylyl cyclase (AC) and PKA activation are primarily responsible for myocyte death induced by ISO. In contrast, when myocytes were stimulated via 2-AR (ISO+CGP or fenoterol), only a small fraction of myocytes died. PKI also blocked this proapoptotic effect. These results agree with those studies showing that the 1-AR is the major mediator of -adrenergic toxicity while 2-AR activation leads to much less myocyte death 21 . The new finding here is that the AC/cAMP/PKA signaling pathway is the exclusive pathway mediating myocyte death, at least in cultured AFVMs. 15 . PKI significantly decreased the percentage of SCMs under this condition ( Figure 5A ). The LTCC blocker, nifedipine (13M), decreased myocyte death induced by ISO and offered no further protection than PKI, indicating that PKI protects myocytes by reducing the increases in LTCC activity caused by -adrenergic stimulation. Intracellular Ca 2+ buffering (BAPTA-AM, 10M) completely blocked GFP-VM death. A specific SERCA inhibitor, thapsigargin (TG, 10nM) 15 also largely blocked ISO induced myocyte death and had no detrimental effects in PKI-VMs ( Figure 5B ). Figure 5C-F) . The blunted response to ISO in PKI-VMs was not due to changes in the expression of Ca 2+ handling proteins (1c, RyR2, calsequestrin, total PLB, NCX1 and SERCA; Figure 6 & Supplemental Figure II) . These results indicate that in AFVMs the positive inotropic effect of chronic ISO stimulation are mediated by PKA and the protective effect of PKI against ISO induced myocyte death is largely mediated by preventing cytosolic and SR Ca 2+ overload.
PKI prevents myocyte apoptosis induced by -AR
ISO induced CaMKII activation is downstream of PKA.
It has been shown that CaMKII plays a critical role in adrenergic 19, 23 and Ca 2+ toxicity 15 in cardiac myocytes. Previous studies have suggested that CaMKII can be activated independently of PKA during chronic -adrenergic stimulation 6-8, 10, 19 . A central role for CaMKII as the mediator of chronic ISO-induced myocyte death was found in our system, since KN93, a CaMKII inhibitor, rescued most GFP-VMs from death induced by ISO ( Figure 6A ). KN93 did not improve PKI-VM survival after ISO exposure.
It is clear that -AR stimulation can activate CaMKII via PKA dependent increases in I Ca-L and SR Ca 2+ 24 . However, others suggest that CaMKII activation seen in myocytes chronically exposed to -agonists is independent of PKA 7, 8, 10, 19 . We explored this issue by measuring PLB phosphorylation at Thr17 (a CaMKII specific phosphorylation site) and CaMKII autophosphorylation at Thr286 in GFPAFVMs and PKI-AFVMs. Myocytes were exposed to ISO for either 10 minutes or 24 hours. PKI inhibited phosphorylation of PLB at both Ser16 (PKA site) and Thr17 (CaMKII site) and Thr286 phosphorylation of CaMKII after acute and chronic ISO treatment ( Figure 6B -E). These results show that in our system CaMKII activation after -AR stimulation is PKA-dependent.
To rule out that the possibility that PKI directly inhibits CaMKII, GFP-AFVMs and PKI-AFVMs were paced or co-infected with AdCav2a (adenovirus containing L-type calcium channel 2a subunit), or treated with an LTCC agonist (FPL 64176, 1M) to activate CaMKII via directly increased cellular [Ca 2+ ], without PKA activation. All these treatments induced PLB Thr17 phosphorylation in both GFPVMs and PKI-VMs. FPL also enhanced CaMKII phosphorylation at Thr286 to the same extend in PKI and GFP-VMs. These data document that PKI does not inhibit CaMKII directly (Supplemental Figure III A-D).
Previous studies 6 suggest that increased intracellular cAMP activates EPAC to activate CaMKII independent of PKA. These studies used 8-cp-TOME, a so-called "EPAC-specific" activator, to activate EPAC. There is evidence that 8-cp-TOME may inhibit phosphodieseterase 25 , leading to increased intracellular cAMP and thus PKA activation. 8-cp-TOME induced phosphorylation of PLB Ser16 (PKA site) and Thr17 (CaMKII site) in GFP-VMs in a dose-dependent manner. 8-cp-TOME could not activate PKA nor CaMKII in PKI-VMs (Supplemental Figure IV) .
Collectively these results suggest that CaMKII activation induced by -adrenergic stimulation is mediated by PKA in AFVMs. To determine if the increase in Ca 2+ influx promoted by PKA activation is responsible for CaMKII activation, myocytes were treated with nifedipine (13M) and ISO (10M). 
-agonists induce cardioprotection in PKI treated myocytes by activating EPAC.
-agonists increase cAMP that is able to activate EPAC. However, EPAC specific effects on myocytes are difficult to evaluate because of parallel PKA activation. In our PKI-VMs, PKA activity is inhibited and this provides a system to evaluate if EPAC regulates cell death signaling. EPAC, as a GTP exchange factor, activates Rap1-GTPase by catalyzing the formation of Rap1-GTP which activates ERK. As predicted, both ISO and 8-cp-TOME exposure increased the amount of Rap1-GTP ( Figure 7A Figure 7B ). 8-cp-TOME protected GFP-VMs and PKI-VMs from death induced by high [Ca 2+ ] o , indicating EPAC offers protection on VMs. In GFP-VMs, forskolin and ISO increased Ca 2+ -mediated myocyte death. In PKI-VMs, forskolin and ISO protected myocytes from Ca 2+ -mediated death and the effect was equivalent to that of 8-Cp-TOME in GFP-VMs (Figure 7 E). These data show that -adrenergic agonists activate proapoptotic signaling via PKA/CaMKII signaling and in parallel activate cardioprotective signaling via EPAC.
EPAC activation induces ERK phosphorylation and phosphorylated ERK protects various cells from death 19, [26] [27] [28] [29] . ERK phosphorylation was increased in both GFP-VM and PKI-VMs exposed to ISO and 8-cp-TOME (0.1M, an EPAC specific activator at low concentrations, Supplemental Figure IV) and Figure 7C and D), indicating that this process is PKA-independent (Figure 7B & C). To confirm that activated ERK is the cardioprotective mediator, an ERK inhibitor, PD 98059, was used to pre-treat AFVMs before the exposure to ISO or 8-cp-TOME and high extracellular Ca 2+ . PD98059 almost completely abolished the protective effects of 8-cp-TOME in both GFP-VMs and PKI-VMs. The protective effect of ISO in PKI-VMs was also abolished by PD98059 ( Figure 7E ). These results strongly support the idea that ERK phosphorylation, downstream of EPAC activation, mediates the protective effects of adrenergic activation.
-blockade eliminates the protective effect of -adrenergic activation.
The present results suggest that 1-AR agonists can induce cell death signaling through PKA and cardioprotective signaling through EPAC/ERK. -AR antagonist therapies could abolish both cardiotoxic and cardioprotective features of -AR activation. Selective block of PKA with PKI in cardiovascular disease could preserve cardioprotective aspects of 1-AR signaling to provide benefit beyond -AR antagonists. To test this idea myocardial infarction (MI) was induced in WT and PKI-DTG mice, with and without concomitant 1-AR antagonist therapy. We used a 1-AR blocker, metoprolol, to induce similar reductions of PKA activity as our PKI-GFP gene does after MI ( Figure 8A ). MI caused a reduction in cardiac function in all animals and both -blocker and PKI improved function. However, PKI-DTG animals had better cardiac function than -blocker treated animals. It seems that metoprolol at the dose used (20mg/kg BW/day) decreased some but did not abolish the beneficial effects of PKI, suggesting that it blocked some but not all cardioprotective adrenergic signaling ( Figure 8B ).
DISCUSSION
Common cardiovascular diseases, such as hypertension and ischemic heart disease, increase the contractile demand of the heart and the SAS is activated to maintain basal cardiac output. Persistent SAS activation is associated with myocyte death and cardiac decompensation, culminating in heart failure. How persistent activation of -ARs induces myocyte death is not clearly defined 4, 5, 19 and was the topic of this study. The specific roles of downstream -AR signaling effectors (PKA, CaMKII and EPAC) were examined. A novel PKA inhibition gene (PKI-GFP) was developed to inhibit PKA in vivo (transgenic mouse) and in vitro (cultured AFVMs infected with AdPKI-GFP). The new findings in this study are: (1) PKI-GFP can inhibit -AR mediated activation of PKA; (2) PKA inhibition with PKI reduces -adrenergic agonist induced myocyte death by preventing myocyte Ca 2+ overload; (3) Inhibition of PKA eliminates -AR induced CaMKII activation; (4) -AR mediated increases in cAMP activates EPAC, and this exerts an ERK-dependent protective effect on myocyte death; (5) PKI protects the heart after MI and a 1-AR antagonist, metoprolol, reduced the protection exerted by PKI. Collectively, these results show that AR signaling can induce both cell death (through PKA, CaMKII and SR Ca 2+ overload) and cardioprotection (through EPAC).
PKA-dependent activation of CaMKII is the mediator of myocyte apoptosis induced by -adrenergic agonists.
Previous studies support the conflicting ideas that CaMKII can be activated by either PKAdependent 30 or PKA-independent 6-8, 10, 30, 31 mechanisms following -adrenergic stimulation 30 . PKAdependent activation of CaMKII is brought about by an increase in Ca 2+ influx through the L-type Ca 2+ channel after PKA-dependent phosphorylation 30 . Recently, it has been reported that EPAC, a cAMP sensor, can activate CaMKII independently of PKA activation in cardiac myocytes [6] [7] [8] [9] . This is an important topic since CaMKII activation is required for myocyte apoptosis induced by -adrenergic stimulation 19, 32, 33 . Inhibition of CaMKII in vivo significantly reduced myocyte apoptosis after isoproterenol stimulation 23 , suggesting that CaMKII would be a useful therapeutic target in CHF. Our results show that -adrenergic stimulation enhances the phosphorylation of the CaMKII site (Thr17) on phospholamban in normal cardiac myocytes. In the presence of PKA inhibition, -adrenergic stimulation had almost no effect on CaMKII autophosphorylation and PLB Thr17 phosphorylation. The present experiments show that when the -adrenergic induced increase in Ca 2+ influx through the L-type Ca 2+ channel is prevented by PKI or blocked by nifedipine, CaMKII activity was eliminated. These results suggest that at least in PKI mice and PKI-infected AFVMs, CaMKII activation is dependent on PKAmediated increase in LTCC activity and subsequent increase in [Ca 2+ ] i . We also show that in the presence of PKA inhibition, -AR agonists activate Rap1 downstream of EPAC activation, but CaMKII is not activated. These results show that EPAC does not cause CaMKII activation under our experimental conditions.
The present results contrast with those studies suggesting a PKA-independent, EPAC-mediated CaMKII activation during -adrenergic stimulation [6] [7] [8] [9] [10] . The bases for these disparate results are not clear but might be due to differences in species, experimental conditions (e.g., concentrations of isoproterenol and 8-cp-TOME) and methods to inhibit PKA. Studies suggesting EPAC mediated CaMKII activation have used rodent myocytes in long-term culture. spontaneous SR Ca 2+ release in long-term culture. The low basal Ca 2+ state of AFVMs allowed us to dissect the role of PKA in mediating -adrenergic induced CaMKII activation. We also found that 8-cp-TOME can activate PKA possibly by indirectly inhibiting phosphodiesterase as suggested by one previous study 25 . The Ki values for PDE1B, PDE2 and PDE6 of 8-cp-TOME are 8.6M, 15M and 3.5M, respectively. Therefore, the interpretation of the results obtained with 10M 8-cp-TOME should be cautious and adequate PKA inhibition should be ensured when evaluating EPAC effects with 8-cp-TOME. Our results clearly showed that in AFVMs when PKA activity is adequately inhibited, 8-cp-TOME cannot activate PKA and CaMKII (supplement Figure IV) .
EPAC is a cardioprotective feature of -adrenergic agonists.
EPAC1 and EPAC2 are highly expressed in the heart but their functions are not well known. They are the guanodine exchange factor for the small GTPases, Rap1 and Rap2. EPAC is thought to exert both pro-and anti-apoptotic effects on cells depending on the cell types and conditions 35 . The role of EPACs in cardiac myoycte apoptosis has not been reported to date. As discussed, EPACs have been suggested to be involved in myocyte apoptosis by activating the proapoptotic multifunctional CaMKII in cardiac myocytes exposed to -adrenergic agonists 36 . Our studies clearly indicate that prolonged treatment of cultured feline myocytes with 0.1M 8-cp-TOME (a concentration sufficient to activate EPAC but not PKA, see Figure 7A ) does not induce myocyte death ( Figure 7B ). Our results show that EPAC protects myocytes from death induced by high extracellular Ca 2+ . EPAC mediated ERK1/2 activation is linked to this protective effects. ERK1/2 activation downstream to EPAC activation has been reported in other cell types 29 .
PKI inhibition of PKA protects the heart after MI.
Excessive adrenergic activation in cardiac disease is linked to heart failure progression, and -AR antagonists improve outcome in CHF patients 3 . Part of the beneficial effect offered by PKA inhibition may be related to both the reduction of Ca 2+ influx and the inhibition of SR Ca 2+ uptake to prevent SR Ca 2+ overload. In contrast, the effectiveness of LTCC blockers in treating failing hearts are controversial
37
. This discrepancy could be due to the fact that LTCC blockers exerts more potent effects on the vascular system than on the heart at the clinical doses 37 . LTCC blockers also have negative inotropic effect that has to be avoided when treating diseased heart. These effects cause a reactive excitation of the SAS to increase serum catecholamines and even cardiac attack. PKA inhibition effectively and specifically reduces Ca 2+ influxes in cardiac myocytes. Therefore, clinically used doses of LTCC blockers cannot be as effective as cardiac specific PKA inhibition to reduce Ca 2+ influx and SR Ca 2+ content to protect stressed hearts.
PKA inhibition could also protect post-MI hearts by decreasing the heart rate to reduce the energy consumption 38 . Although at baseline, we did not observe difference in heart rates between control and DTG mice (basal HR: control 560±16bpm, n=8; DTG: 544±15bpm, n=8), DTG hearts had reduced response to ISO stimulation (HR after ISO (2mg/kg BW, i.p.): control 752±24bpm, n=8; DTG: 603±14bpm, n=8). Our study suggests that the detrimental aspects of -AR signaling in HF are mediated by PKA signaling, while parallel PKA-independent signaling is cardioprotective. Our data suggest that beneficial effects of -adrenergic activation would be reduced with the use of -adrenergic antagonists (Figure 8 ). These beneficial effects could result from cAMP-mediated effects via EPAC or from "biased ligand" effects shown by others 39 .
CONCLUSION
The present study shows that chronic exposure of the heart to -adrenergic agonists, as occurs in heart failure, causes myocyte death. The mechanism involves cAMP mediated activation of PKA and resultant increase in Ca 2+ influx and SR Ca 2+ load. Ca 2+ mediated activation of CaMKII is dependent on PKA activation. -adrenergic mediated increase in cAMP also activates EPAC to induce a cardioprotective effect. These results suggest that selective inhibition of excessive PKA activation could be an effective CHF therapy.
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DISCLOSURES
Novelty and Significance
What Is Known?
 The -adrenergic/sympathetic system is constantly activated when the heart is under stress.
 Persistently activated -adrenergic system induces chronic loss of contractile heart cells (cardiomyocytes) via apoptosis.
 PKA, CaMKII and EPAC are activated during chronic -adrenergic stimulation and CaMKII is required for -adrenergic agonist induced cardiac myocyte apoptosis but the roles of PKA and EPAC are still controversial.
What New Information Does This Article Contribute?
 PKA inhibition prevents myocyte death induced by -adrenergic stimulation and myocardial infarction in vivo and in vitro.
 CaMKII is activated by increased cytosolic Ca 2+ that is brought about by PKA to mediate myocyte apoptosis.
 EPAC activation in the presence of PKA inhibition protects cardiomyocytes from death through the prosurvival ERK signaling pathway.
Chronic activation of the -adrenergic system after cardiac stress leads to the loss of contractile heart cells (cardiomyocytes), an important contributor to the progression of heart disease. Though PKA, CaMKII and EPAC are three effectors activated by the adrenergic system, the roles of these molecules in -adrenergic induced myocyte death are controversial. In the study, we used a genetic tool to suppress PKA activity in cardiomyocyte in a transgenic mouse model and in cultured myocytes to explore their roles. We have proven that PKA is an important mediator of myocyte death and myocardial remodeling after -adrenergic agonist challenge and myocardial infarction. The proapoptotic mediator CaMKII during -adrenergic stimulation is activated by increased cellular Ca 2+ caused by PKA. Furthermore, for the first time, we show that EPAC activation protects myocytes from death through the prosurvival ERK signaling and PKA inhibition provides better protection than metoprolol at the dose offering similar PKA activity reduction. Collectively, our data show that the -adrenergic system carries both detrimental and protective effects when activated, which is a novel finding. Therefore, PKA inhibition as a strategy to abolish the harmful signaling but preserves the protective signaling could be a novel approach for heart disease treatment. 
SUPPLEMENTAL DATA
Materials and Methods
PKI-GFP fusion gene and adenovirus (AdPKI) production:
A DNA oligo corresponding to the coding sequence for amino acids 1-25 (MTDVETTYADFIASGRTGRRNAIHD) of mouse protein kinase (cAMP-dependent, catalytic) inhibitor α (PKIα) (mouse Entrez gene ID 18767) was synthesized and subcloned into plasmid pAcGFP1-N1 (Clontech) to make a PKI-GFP fusion gene. Amino acids 1-25 of PKIα have the PKA inhibitory domain 1 but not the nuclear export signal 2 . Then an adenovirus containing the fusion gene was made and further amplified in HEK293 cells. AdPKI-GFP was purified with Adeno-X purification kit and titrated with Adeno-X Rapid Titration kit (Clontech). We have successfully produced this adenovirus with a titer of 10 10 -10 12 pfu/ml. An adenovirus carrying GFP gene alone (AdGFP) was amplified, titrated the same way and used as control.
Transgenic mouse model overexpressing PKI-GFP and isoproterenol treatment: Transgenic mice overexpressing PKI-GFP was made with the inducible, cardiac specific transgenic mouse system developed by the Robbin's group 3 . In this system, the transgene can be expressed only in mice containing both the driver gene tTA and the responder gene PKI-GFP (double transgenic, DTG) without doxycycline. Littermate mice without any transgene (wild type, WT) or with only one transgene (tTA or PKI-GFP; single transgenic, STG) with matched age and sex were used as controls. To prevent the effects of PKA inhibition on cardiac development, PKI-GFP transgene expression was turned off during fetal and postnatal developmental stages by supplying doxycycline (625ppm) containing chow to the breeding parents and pre-weaning pups. In this system, doxycycline is gradually cleared out of the animal after weaning and transgene expression usually begins at around the age of 2 months and reaches maximal expression levels at the age of 4 months. Mice at the age of 4 months when PKI-GFP is fully expressed were used. To study short-term ISO effect on myocyte death, a single dose of isoproterenol (ISO, 60 mg/kg body weight (BW), i.p.) was injected and the heart was harvested and fixed at 8 hours post injection. To examine long-term ISO effect on myocyte death, ISO (60 mg/kg/day) was delivered by osmotic minipump (Alzet model #1002) for 3 weeks and then the heart was harvested and fixed. Cardiac function and morphology before and 3 weeks after ISO infusion were evaluated with echocardiography with a Vevo 707 machine (Visusonics, Toronto, Canada) 4 . Ejection fraction was measured with M-mode to indicate the contractility of the heart. Fixed hearts were sliced into 1mm-thick slices and processed, embedded and sectioned according to standard histological procedure.
Myocardial infarction and treatments:
Myocardial infarction was introduced by ligating the left anterior descending coronary artery at the middle level in 4 month old PKI DTG and control mice as described previously 5, 6 . Echocardiography was performed 2 days before the surgery and then every week after surgery 5 . MI mice were divided into four groups for different treats: control and PKI DTG mice receiving saline or metoprolol (20 mg/kg BW/day 7 ) daily injection for 4 weeks after MI. The dose of metoprolol that inhibits PKA activity to the same level as our PKI was used.
Histology: Hearts were harvested and fixed at specified time points with perfusion fixation as described previously 4 . Cardiac tissue was processed, embedded and sectioned according to standard histology procedure. Masson's Trichrome staining and TUNEL staining on sections were performed as previously described . PKA inhibition prevents 8-cp-TOME induced PLB phosphorylation at both PKA and CaMKII sites. AFVMs infected with AdGFP or AdPKI were exposed to 8-cp-TOME for 10 min (0.1-10 µM). Total PLB, pSer16 PLB and pThr17 PLB were measured with Western blotting (A). B. PKA activity measured with PKA activity probe (AKAR) in live neonatal rat ventricular myocytes. The change of FRET signal indicates PKA activation and 8-cp-TOME AM at 1 and 10 µM activates PKA but 0.1µM 8-cp-TOME AM did not. C. Time course of FRET signal change in response to 10µM 8-cp-TOME AM.
